2017 Pharma Sales: A New Global Order
As the reality of annual results arrive, Scrip predicts how the top of the pharma league table is likely to change.
You may also be interested in...
From 'breakthrough' designations to manufacturing hiccups, numerous review and development challenges await the combined entity.
Takeda is clearly keen on Shire's rare disease therapies, but the future of the ophthalmology business, and notably the dry eye drug Xiidra, is less certain. The shutters may close on Shire's headquarters in Ireland as well.
It is coming up to half-year results season and two things are entirely predictable: there will be many surprises and hardly any of them will be good.